Dupilumab
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Eosinophilic Esophagitis
Conditions
Eosinophilic Esophagitis
Trial Timeline
Jun 16, 2022 → Jan 21, 2025
NCT ID
NCT05247866About Dupilumab
Dupilumab is a approved stage product being developed by Sanofi for Eosinophilic Esophagitis. The current trial status is completed. This product is registered under clinical trial identifier NCT05247866. Target conditions include Eosinophilic Esophagitis.
What happened to similar drugs?
5 of 16 similar drugs in Eosinophilic Esophagitis were approved
Approved (5) Terminated (2) Active (9)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05906706 | Pre-clinical | Completed |
| NCT07316114 | Pre-clinical | Recruiting |
| NCT07467564 | Pre-clinical | Recruiting |
| NCT07187089 | Approved | Withdrawn |
| NCT07112378 | Phase 3 | Recruiting |
| NCT07052396 | Pre-clinical | Recruiting |
| NCT07276425 | Pre-clinical | Recruiting |
| NCT06695897 | Pre-clinical | Recruiting |
| NCT06693531 | Pre-clinical | Recruiting |
| NCT06415175 | Pre-clinical | Active |
| NCT06556264 | Approved | Recruiting |
| NCT06352073 | Approved | Recruiting |
| NCT06293053 | Phase 3 | Recruiting |
| NCT05983068 | Approved | Active |
| NCT06234761 | Pre-clinical | Recruiting |
| NCT05991323 | Pre-clinical | Active |
| NCT06192563 | Pre-clinical | Recruiting |
| NCT06169527 | Pre-clinical | Active |
| NCT06393946 | Pre-clinical | Active |
| NCT05831176 | Phase 2 | Active |
Competing Products
20 competing products in Eosinophilic Esophagitis